MEDTRONIC TRANSFORM CARDIOMYOSTIMULATOR DEVICE PHASE IV TRIAL UNDERWAY
This article was originally published in The Gray Sheet
Executive Summary
MEDTRONIC TRANSFORM CARDIOMYOSTIMULATOR DEVICE PHASE IV TRIAL UNDERWAY at 20 U.S. and foreign medical centers. The company gained FDA approval of a supplemental investigational device exemption in August for the 600-patient, randomized study of the Model SP 1005 Transform.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.